.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
Federal Trade Commission
Healthtrust
Deloitte
UBS
QuintilesIMS
Accenture
Colorcon
Boehringer Ingelheim

Generated: September 24, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Method of preventing NMDA receptor complex-mediated Neuronal damage
Abstract:Disclosed is a method for decreasing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitroso-compound that generates nitric-oxide or related redox species, in a concentration effective to effect neuroprotection. Also disclosed is a method for decreasing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitroso-compound that generates nitric oxide (or a related redox species such as NO.sup.- or NO.sup.+ equivalent), or a physiologically concentration effective to cause such neuroprotection.
Inventor(s): Lipton; Stuart A. (Newton, MA)
Assignee: The Children's Medical Center Corporation (Boston, MA)
Filing Date:Mar 22, 1995
Application Number:08/407,973
Claims:1. A method for a preliminary screen of candidate NMDA channel antagonists for safety and efficacy, said method comprising

a) determining the time period required for the candidate to induce blockade of NMDA-receptor-associate ion channels;

b) determining the time period required for loss of said blockade of ion channels when administration of the compound ceases; and

c) selecting a compound with time periods (a) and (b) that are shorter than the time periods characteristic of MK-801, thereby enhancing the prospect that the candidate will be a clinically tolerated selective NMDA antagonist.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Daiichi Sankyo
AstraZeneca
Teva
Covington
Cerilliant
McKinsey
Julphar
Argus Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot